英国药品监管局 MHRA 11月16日启动女性健康计划:4616份临床试验申请中孕妇仅占1.1%

英国药品和健康产品监管局(MHRA)11月16日宣布启动女性健康计划,目标是补上药品和医疗器械在女性身上证据不足的缺口,包括风险和获益可能因性别而不同的问题。
MHRA 对2019年至2023年提交的全部4616份英国临床试验申请所作的分析显示,孕妇只出现在1.1%的试验中,哺乳期女性只占0.6%。该局表示,女性占人口的51%,但在临床研究中长期代表性不足,怀孕和生殖健康方面的证据尤其有限。
女性健康大臣 Gillian Merron 表示,女性健康长期被忽视,新计划将与更新后的英格兰女性健康战略配合,带来更好的证据和治疗。MHRA 首席执行官 Lawrence Tallon 表示,弄清药品和器械的风险与获益如何因女性而不同,既是挑战也是机会。
该计划在11月16日至17日于伦敦举行的首届 DIA-MHRA 全球峰会上宣布,峰会是伦敦生命科学周的一部分。MHRA 还将于12月9日举行网络研讨会介绍该计划。英国女性科技领域年营业额已接近3亿英镑。
UK MHRA Launches Women's Health Programme on 16 November: Pregnant Women in Just 1.1% of 4,616 Trial Applications
The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced on 16 November the launch of its Women's Health Programme, aimed at tackling evidence gaps on medicines and medical devices, including how their risks and benefits may differ for women.
An MHRA analysis of all 4,616 UK clinical trial applications submitted between 2019 and 2023 found pregnant women represented in just 1.1% of trials and breastfeeding women in 0.6%. The agency said women make up 51% of the population but have historically been underrepresented in clinical research, limiting evidence during pregnancy and across reproductive health.
Women's Health Minister Baroness Gillian Merron said women's health had been overlooked for too long and that the programme, together with the renewed Women's Health Strategy for England, would mean better evidence and better treatments. MHRA Chief Executive Lawrence Tallon said closing the gaps in understanding how risks and benefits differ for women was both a challenge and a huge opportunity.
The announcement was made at the inaugural DIA-MHRA Global Summit in London on 16-17 November 2026, part of London Life Sciences Week. The MHRA will host a webinar on 9 December introducing the programme. The UK FemTech sector already has an annual turnover of nearly 300 million pounds.
发布:GSM·美国(发布链接)
图片来源:Wikimedia Commons, File:10 South Colonnade and Canary Wharf DLR (south side).jpg, CC BY-SA
GSM Global · 本篇英文版 English edition of this story

